HarborPath Receives Merck Foundation Grant in Support of Low-Income, Uninsured Patients Diagnosed with Hepatitis C
Columbia, SC – March 2, 2016 HarborPath, an organization which provides a single point of access to HIV/AIDS medications through its patient assistance program, has been awarded a grant from the Merck Foundation, a U.S.-based, private charitable foundation. The grant funds will be used to support hepatitis C program operations for the inclusion of Merck’s new chronic hepatitis C medication, Zepatier, with HarborPath’s expanded portal program offerings for qualified, uninsured individuals who otherwise may not receive medication critical to their health.
“We are very honored that Merck has chosen to offer Zepatier to uninsured patients through the HarborPath portal. Merck has been an essential partner for our organization from inception, and we are excited to continue this vital partnership to the benefit of many uninsured people. This grant funding will allow us to begin a program for people living with hepatitis C who would otherwise have no access to this life-saving medication,” remarked Ken Trogdon, Jr., President of HarborPath.
HarborPath provides an online portal which streamlines the process for healthcare professionals and case managers to apply for medications on behalf of uninsured individuals living with chronic, life-threatening diseases, such as HIV/AIDS and hepatitis C. Through one online application, multiple medications can be accessed from HarborPath’s participating manufacturers. The donated medications are delivered at no cost to qualified individuals through HarborPath’s contract mail-order pharmacy.
HarborPath is a 501(c) (3) organization whose mission is to provide streamlined access to HIV/AIDS medications through patient assistance programs via an online portal. For more information, visit www.harborpath.org.
Mike Beyer Sam Brown Inc. PR for HarborPath
Ken Trogdon, Jr.